SEARCH:   Advanced

Blood, 1 October 2008, Vol. 112, No. 7, pp. 2703-2708. Prepublished online as a Blood First Edition Paper on June 6, 2008; DOI 10.1182/blood-2008-02-142422. This Article Full Text (PDF) All Versions of this Article: blood-2008-02-142422v1 112/7/2703    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ay, C. Articles by Pabinger, I. Search for Related Content PubMed PubMed Citation Articles by Ay, C. Articles by Pabinger, I. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 26, 2008 Accepted May 15, 2008 High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients - results from the Vienna Cancer and Thrombosis Study (CATS) Cihan Ay, Ralph Simanek, Rainer Vormittag, Daniela Dunkler, Guelay Alguel, Silvia Koder, Gabriela Kornek, Christine Marosi, Oswald Wagner, Christoph Zielinski, and Ingrid Pabinger* Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria Core Unit for Medical Statistics and Informatics, Section of Clinical Biometrics, Medical University of Vienna, Vienna, Austria Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria * Corresponding author; email: ingrid.pabinger{at}meduniwien.ac.at. Cancer patients are at high risk for venous thromboembolism (VTE). Laboratory parameters with a predictive value for VTE could help stratify patients into high- or low-risk groups. Recently the cell adhesion molecule P-selectin was identified as risk factor for VTE. To investigate soluble P-selectin (sP-selectin) in cancer patients as risk predictor for VTE, we performed a prospective cohort study of 687 cancer patients and followed them up for a median [IQR] of 415 [221-722] days. Main tumour entities were malignancies of the breast (n=125), lung (n=86), gastrointestinal tract (n=130), pancreas (n=42), kidney (n=19), prostate (n=72), brain (n=80); 91 had hematologic malignancies and 42 other tumours. VTE occurred in 44 (6.4%) patients. In multivariable analysis elevated sP-selectin (cut-off level 53.1 ng/mL, 75th percentile of the study population) was a statistically significant risk factor for VTE after adjustment for age, sex, surgery, chemo- and radiotherapy (hazard ratio: 2.6, 95% CI 1.4-4.9, p=0.003). The cumulative probability of VTE after 6 months was 11.9% in patients with sP-selectin above and 3.7% in those below the 75th percentile (p=0.002). High sP-selectin plasma levels independently predict VTE in cancer patients. Measurement of sP-selectin at diagnosis of cancer could help identify patients at increased risk for VTE. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: P-selectin ready for prime time? Punam Rana, Jim Julian, and Mark Levine Blood 2009 113: 1860. [Full Text] [PDF] Response: P-selectin ready for the "News at Six" Cihan Ay and Ingrid Pabinger Blood 2009 113: 1860-1861. [Full Text] [PDF] Cancer and thrombosis is a sticky business Frederick R. Rickles Blood 2008 112: 2594-2595. [Full Text] [PDF] This article has been cited by other articles: A. A. Khorana and G. C. Connolly Assessing Risk of Venous Thromboembolism in the Patient With Cancer J. Clin. Oncol., October 10, 2009; 27(29): 4839 - 4847. [Abstract] [Full Text] [PDF] E. PAN, J. S. TSAI, and S. B. MITCHELL Retrospective Study of Venous Thromboembolic and Intracerebral Hemorrhagic Events in Glioblastoma Patients Anticancer Res, October 1, 2009; 29(10): 4309 - 4313. [Abstract] [Full Text] [PDF] C. Ay, R. Vormittag, D. Dunkler, R. Simanek, A.-L. Chiriac, J. Drach, P. Quehenberger, O. Wagner, C. Zielinski, and I. Pabinger D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study J. Clin. Oncol., September 1, 2009; 27(25): 4124 - 4129. [Abstract] [Full Text] [PDF] M. Mandala, S. Barni, M. Prins, R. Labianca, C. Tondini, L. Russo, A. Milesi, M. Cremonesi, M. Zaccanelli, C. Regonesi, et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial Ann. Onc., August 27, 2009; (2009) mdp354v1. [Abstract] [Full Text] [PDF] T. Sousou and A. A. Khorana New Insights Into Cancer-Associated Thrombosis Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 316 - 320. [Abstract] [Full Text] [PDF] I. Pabinger and C. Ay Biomarkers and Venous Thromboembolism Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 332 - 336. [Abstract] [Full Text] [PDF] P. Rana, J. Julian, and M. Levine P-selectin ready for prime time? Blood, February 19, 2009; 113(8): 1860 - 1860. [Full Text] [PDF] C. Ay and I. Pabinger Response: P-selectin ready for the "News at Six" Blood, February 19, 2009; 113(8): 1860 - 1861. [Full Text] [PDF] A. A. Khorana and G. H. Lyman Incidence and Prevention of Cancer-associated Thrombosis ASCO Educational Book, January 1, 2009; 2009(1): 321 - 325. [Abstract] [Full Text] [PDF] Predicting Venous Thromboembolism in Cancer Patients Journal Watch Oncology and Hematology, November 18, 2008; 2008(1118): 2 - 2. [Full Text]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020